---
title: "Alumis Shareholders Reelect Directors and Ratify Auditor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291590478.md"
description: "Alumis Inc. held its 2026 Annual Meeting, reelecting James B. Tananbaum, Lynn Tetrault, and Zhengbin Yao as Class II directors and ratifying PricewaterhouseCoopers LLP as the independent auditor. While analysts maintain a 'Buy' rating with a $51 target, TipRanks’ AI analyst rates ALMS as 'Neutral' due to weak financial performance despite strong technicals and positive clinical data."
datetime: "2026-07-02T21:10:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291590478.md)
  - [en](https://longbridge.com/en/news/291590478.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291590478.md)
generator: "portal-rs"
---

# Alumis Shareholders Reelect Directors and Ratify Auditor

Alumis Inc. ( (ALMS) ) has provided an update.

On June 30, 2026, Alumis Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected James B. Tananbaum, Lynn Tetrault and Zhengbin (Bing) Yao as Class II directors to serve until the 2029 annual meeting. The election results, with strong majorities for all three candidates, reinforced continuity on the company’s board and signaled broad investor support for its current leadership.

At the same meeting, stockholders ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026. This ratification confirms shareholder backing for the company’s existing audit arrangements, supporting ongoing confidence in Alumis’s financial oversight and reporting practices.

The most recent analyst rating on (ALMS) stock is a Buy  
 with a $51.00 price target.  
 To see the full list of analyst forecasts on Alumis Inc. stock,  
 see the ALMS Stock Forecast page. 

**Spark’s Take on ALMS Stock**

According to Spark, TipRanks’ AI Analyst, ALMS is a Neutral.

The score is held back primarily by weak financial performance (steep revenue decline, large losses, and heavy cash burn), despite a supportive low-leverage balance sheet. Offsetting this, technicals are strong with the stock trading above key moving averages and positive momentum, and recent corporate events highlight encouraging Phase 3 data and forthcoming milestones. Valuation remains constrained by negative earnings and no dividend support.

To see Spark’s full report on ALMS stock,  
 click here. 

**More about Alumis Inc.**

Alumis Inc. is a publicly traded company whose common stock is widely held, with more than 123 million voting shares outstanding as of May 5, 2026. The company operates under U.S. corporate governance norms, holding annual stockholder meetings and engaging a major global audit firm to oversee its financial reporting for investors.

**Average Trading Volume:** 1,261,399

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $3.4B

For a thorough assessment of ALMS stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md)

## Related News & Research

- [Alumis (NASDAQ:ALMS) Shares Up 7.6% After Analyst Upgrade](https://longbridge.com/en/news/297930765.md)
- [ALMS: Envudeucitinib showed strong efficacy in IFNGS-high SLE patients and was well tolerated](https://longbridge.com/en/news/297666957.md)
- [Alumis says Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus misses primary endpoint](https://longbridge.com/en/news/297644348.md)
- [BUZZ-Alumis tumbles after lupus drug misses main goal in mid-stage trial](https://longbridge.com/en/news/297657950.md)
- [Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/296693396.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**